Shares of MediciNova (MNOV), a small biotech, rose sharply Monday, but for a reason that may not hold up to scientific scrutiny.
MediciNova announced the early termination of a mid-stage study because of positive results in patients with NASH, or nonalcoholic steatohepatitis, a fatty liver disease. MediciNova shares rose 20 percent to $12.33.
About the Author Reprints
A cheap way to cut triglycerides is to consume less sugar. Treating the symptoms of a bad diet is not good medicine but slipstreaming the soft drinks industry is probably excellent business